What amycretin is and who makes it
Amycretin is a Novo Nordisk medicine that acts on both GLP-1 and amylin receptors in a single molecule. It is being studied as a once-weekly injection and as a once-daily tablet. Novo Nordisk's 2025 annual report refers to it as zenagamtide, formerly known as amycretin.
Sources: Novo Nordisk Annual Report 2025: innovation and therapeutic focus.
Trial stage and published results
The published results so far come from early trials. In a phase 1b/2a trial of the weekly injection, published in The Lancet in 2025, 125 adults with overweight or obesity took amycretin or placebo for up to 36 weeks. Novo Nordisk reports weight reductions of up to 24.3% at the highest doses after 36 weeks, against 1.1% with placebo. A small early trial like this cannot show how the medicine will perform in the larger phase 3 trials.
Novo Nordisk says the most frequent side effects were digestive and mild or moderate, and became more frequent at higher doses.
On 12 June 2025 Novo Nordisk announced it would move both the injection and the tablet into phase 3 trials for weight management. Its 2025 annual report says that phase 3 programme was underway in the first quarter of 2026.
Sources: The Lancet: Dahl et al., amycretin administered subcutaneously, phase 1b/2a (2025); Novo Nordisk: amycretin results presented at ADA 2025; Novo Nordisk: amycretin to phase 3, 12 June 2025.
EU and Irish regulatory status
Amycretin is not authorised by any regulator. The EMA's list of new medicines under evaluation, with data extracted on 5 October 2026, has no entry for amycretin or zenagamtide, and we found no announced application in the EU, the US or the UK.
When could it be available in Ireland?
A new weight-loss medicine like this reaches Irish prescribers through the European Medicines Agency. The EMA says its committee's scientific assessment takes up to 210 active days, not counting the pauses while the company answers questions, and the European Commission then decides within 67 days of the committee's opinion. A company launch and pharmacy stock in Ireland come after that.
Our estimate, not a company date: phase 3 trials that started in 2026 still have to finish and report before any EU application, so availability through an Irish prescriber before 2029 looks unlikely. Novo Nordisk has not published a filing or launch date; the real date is UNKNOWN.
Sources: EMA: obtaining an EU marketing authorisation, step by step.
What about websites selling it now?
No authorised version of amycretin exists, so a product sold online under this name is not an approved medicine and may contain anything. We do not list these sellers or their prices. Read the HPRA's warning about buying medicines online.
What people in Ireland can use now
Authorised GLP-1 medicines for weight management, such as Wegovy and Mounjaro, are prescription-only and are prescribed after a clinical assessment. Our guide to getting a GLP-1 prescription in Ireland explains the routes, and the eligibility check shows which ones may fit your BMI and health. Neither offers access to amycretin.